162 related articles for article (PubMed ID: 25814778)
41. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
42. [Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women].
Mestiri S; Monastiri K; Ben Ahmed S; Bouaouina N; Presneau N; Bignon YJ; Khairi H; Chouchane L
Arch Inst Pasteur Tunis; 2000; 77(1-4):11-5. PubMed ID: 14658222
[TBL] [Abstract][Full Text] [Related]
43. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
44. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
[TBL] [Abstract][Full Text] [Related]
45. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
46. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
47. A high proportion of founder BRCA1 mutations in Polish breast cancer families.
Górski B; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Grzybowska E; Mackiewicz A; Stawicka M; Bebenek M; Sorokin D; Fiszer-Maliszewska Ł; Haus O; Janiszewska H; Niepsuj S; Góźdź S; Zaremba L; Posmyk M; Płuzańska M; Kilar E; Czudowska D; Waśko B; Miturski R; Kowalczyk JR; Urbański K; Szwiec M; Koc J; Debniak B; Rozmiarek A; Debniak T; Cybulski C; Kowalska E; Tołoczko-Grabarek A; Zajaczek S; Menkiszak J; Medrek K; Masojć B; Mierzejewski M; Narod SA; Lubiński J
Int J Cancer; 2004 Jul; 110(5):683-6. PubMed ID: 15146557
[TBL] [Abstract][Full Text] [Related]
48. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.
Tommasi S; Crapolicchio A; Lacalamita R; Bruno M; Monaco A; Petroni S; Schittulli F; Longo S; Digennaro M; Calistri D; Mangia A; Paradiso A
Mutat Res; 2005 Oct; 578(1-2):395-405. PubMed ID: 16026807
[TBL] [Abstract][Full Text] [Related]
49. BRCA1 screening in patients with a family history of breast or ovarian cancer.
Arver B; Claro A; Langerød A; Børresen-Dale AL; Lindblom A
Genet Test; 1999; 3(2):223-6. PubMed ID: 10464672
[TBL] [Abstract][Full Text] [Related]
50. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
[TBL] [Abstract][Full Text] [Related]
51. Non-founder BRCA1 mutations in Russian breast cancer patients.
Iyevleva AG; Suspitsin EN; Kroeze K; Gorodnova TV; Sokolenko AP; Buslov KG; Voskresenskiy DA; Togo AV; Kovalenko SP; Stoep Nv; Devilee P; Imyanitov EN
Cancer Lett; 2010 Dec; 298(2):258-63. PubMed ID: 20727672
[TBL] [Abstract][Full Text] [Related]
52. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
53. Identification of Novel
Mighri N; Hamdi Y; Boujemaa M; Othman H; Ben Nasr S; El Benna H; Mejri N; Labidi S; Ayari J; Jaidene O; Bouaziz H; Ben Rekaya M; M'rad R; Haddaoui A; Rahal K; Boussen H; Boubaker S; Abdelhak S
Front Genet; 2020; 11():552971. PubMed ID: 33240314
[TBL] [Abstract][Full Text] [Related]
54. BRCA mutation screening and patterns among high-risk Lebanese subjects.
Farra C; Dagher C; Badra R; Hammoud MS; Alameddine R; Awwad J; Seoud M; Abbas J; Boulos F; El Saghir N; Mukherji D
Hered Cancer Clin Pract; 2019; 17():4. PubMed ID: 30675319
[TBL] [Abstract][Full Text] [Related]
55. BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review.
Neamatzadeh H; Shiryazdi SM; Kalantar SM
J Res Med Sci; 2015 Mar; 20(3):284-93. PubMed ID: 26109977
[TBL] [Abstract][Full Text] [Related]
56. Searching for new breast cancer-associated genes. ABRAXAS1 gene mutations in the group of BRCA1-negative patients.
Bąk A; Junkiert-Czarnecka A; Heise M; Januchowska D; Krzywińska O; Haus O
Pol J Pathol; 2018; 69(4):342-346. PubMed ID: 30786683
[TBL] [Abstract][Full Text] [Related]
57. Management of breast cancer patients with
El Saghir NS; Ghanem H; El Karak F; Farhat F; Ghosn M; Makdessi J; Chouaib K; Debs J; Tabchy AB
Hosp Pract (1995); 2021 Dec; 49(5):325-329. PubMed ID: 34547975
[TBL] [Abstract][Full Text] [Related]
58. Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer.
Gomes R; Soares BL; Felicio PS; Michelli R; Netto CBO; Alemar B; Ashton-Prolla P; Palmero EI; Moreira MÂM
Genet Mol Biol; 2020; 43(2):e20190072. PubMed ID: 32453342
[TBL] [Abstract][Full Text] [Related]
59. Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East.
Romdhane L; Kefi R; Azaiez H; Ben Halim N; Dellagi K; Abdelhak S
Orphanet J Rare Dis; 2012 Aug; 7():52. PubMed ID: 22908982
[TBL] [Abstract][Full Text] [Related]
60. New Insights Into c.815_824dup Pathogenic Variant of
Diop JPD; Sène ARG; Dia Y; Ba SA; Mbacke SS; Ly CAT; Sarr PD; Diouf D; Ka S; Mbengue B; Gueye SMK; Diop PS; Sylla Niang M; Gueye PM; Lopez Sall P; Dem A; Cisse A; Dieye A; Ndiaye R
Front Oncol; 2021; 11():810060. PubMed ID: 35096615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
